商品名称 | 适用类别 | 通用名称 | 活性成分 | 产品号 | 上市许可开发者/申请人/持有人 | 上市许可日期 | 许可状态 |
---|---|---|---|---|---|---|---|
Hukyndra | Human | adalimumab | adalimumab | EMEA/H/C/005548 | Stada Arzneimittel AG | 2021/11/15 | Authorised |
Libmyris | Human | adalimumab | adalimumab | EMEA/H/C/005947 | Stada Arzneimittel AG | 2021/11/12 | Authorised |
Yuflyma | Human | adalimumab | adalimumab | EMEA/H/C/005188 | Celltrion Healthcare Hungary Kft. | 2021/02/11 | Authorised |
Amsparity | Human | adalimumab | adalimumab | EMEA/H/C/004879 | Pfizer Europe MA EEIG | 2020/02/13 | Authorised |
Idacio | Human | adalimumab | adalimumab | EMEA/H/C/004475 | Fresenius Kabi Deutschland GmbH | 2019/04/02 | Authorised |
Kromeya | Human | adalimumab | adalimumab | EMEA/H/C/005158 | Fresenius Kabi Deutschland GmbH | 2019/04/02 | Withdrawn |
Hulio | Human | adalimumab | adalimumab | EMEA/H/C/004429 | Biosimilar Collaborations Ireland Limited | 2018/09/17 | Authorised |
Hyrimoz | Human | adalimumab | adalimumab | EMEA/H/C/004320 | Sandoz GmbH | 2018/07/26 | Authorised |
Hefiya | Human | adalimumab | adalimumab | EMEA/H/C/004865 | Sandoz GmbH | 2018/07/26 | Authorised |
Halimatoz | Human | adalimumab | adalimumab | EMEA/H/C/004866 | Sandoz GmbH | 2018/07/26 | Withdrawn |
Cyltezo | Human | adalimumab | adalimumab | EMEA/H/C/004319 | Boehringer Ingelheim International GmbH | 2017/11/10 | Withdrawn |
Imraldi | Human | adalimumab | adalimumab | EMEA/H/C/004279 | Samsung Bioepis NL B.V. | 2017/08/24 | Authorised |
Solymbic | Human | adalimumab | adalimumab | EMEA/H/C/004373 | Amgen Europe B.V. | 2017/03/22 | Withdrawn |
Amgevita | Human | adalimumab | adalimumab | EMEA/H/C/004212 | Amgen Europe B.V. | 2017/03/21 | Authorised |
Humira | Human | adalimumab | adalimumab | EMEA/H/C/000481 | AbbVie Deutschland GmbH Co. KG | 2003/09/08 | Authorised |
Trudexa | Human | adalimumab | adalimumab | EMEA/H/C/000482 | Abbott Laboratories Ltd. | 2003/09/01 | Withdrawn |
Fyzoclad | Human | adalimumab | adalimumab | EMEA/H/C/005253 | Pfizer Europe MA EEIG | Application withdrawn |